Article thumbnail

A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections

By Inge C. Gyssens, Matthew Dryden, Peter Kujath, Dilip Nathwani, Nicolaas Schaper, Barbara Hampel, Peter Reimnitz, Jeff Alder and Pierre Arvis
Topics: Original Research
Publisher: Oxford University Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1997). a new fluoroquinolone. Antimicrob Agents Chemother
  2. (2003). A severity score for complicated skin and soft tissue infections derived from Phase III studies of linezolid.
  3. (2011). Antimicrobial Resistance Surveillance
  4. (2010). Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres.
  5. (2007). Bacteriology of moderate– severe diabetic foot infections and in vitro activity of antimicrobial agents.
  6. (1996). Classification of diabetic foot wounds.
  7. (2009). Clostridium difficile and fluoroquinolones: is there a link?
  8. (2011). Clostridium difficile infection in an endemic setting in the Netherlands.
  9. (1997). Comparison of the in vitro activities of BAY 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother
  10. (2004). Complicated infections of skin and skin structures: when the infection is more than skin deep.
  11. (2004). Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev
  12. (2005). Effect of recombinant murine granulocyte colony-stimulating factor with or without fluoroquinolone therapy on mixed-infection abscesses in mice. Antimicrob Agents Chemother
  13. (2009). Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. Infection
  14. (2005). Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet
  15. Managing skin and soft tissue infections: expert panel recommendations on key decision points.
  16. (2010). Meta-analysis of trials evaluating parenteral antimicrobial therapy for skin and soft tissue infections. Clin Infect Dis
  17. (2003). Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med
  18. (2007). Microbial spectrum and antibiotic susceptibility profile of Gram-positive aerobic bacteria isolated from cancer patients.
  19. Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis.
  20. (2006). Moxifloxacin in the treatment of skin and skin structure infections. Ther Clin Risk Management
  21. (1999). Optimal treatment of complicated skin and skin structure infections.
  22. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother
  23. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.
  24. (1999). Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother
  25. (2007). Preemptive isolation to prevent meticillin-resistant Staphylococcus aureus cross-transmission in diabetic foot. Diabetes Care
  26. (2006). Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect
  27. (2004). Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther
  28. (2005). Sequential intravenous/oral moxifloxacin versus intravenous piperacillin–tazobactam followed by oral amoxicillin–clavulanate for the treatment of complicated skin and skin structure infection.
  29. (1996). Soft tissue infections among injection drug users –
  30. (2007). soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes.
  31. (2009). Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV study).
  32. (2009). Temporal effects of antibiotic use and Clostridium difficile infections.
  33. (1981). The dysvascular foot: a system for diagnosis and treatment. Foot Ankle
  34. (1997). The substitution of digital images for dermatologic physical examination. Arch Dermatol
  35. (2007). Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin–tazobactam/amoxicillin–clavulanate.
  36. (2004). Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin–sulbactam/amoxicillin–clavulanate. Clin Infect Dis
  37. (1998). Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care